Evidence map›Paper›PMID 37684511›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.

Roberta Bovenzi, Claudio Liguori, Margherita Canesi, Marco D'Amelio, Maria Francesca De Pandis, Carmine Marini, Alessandra Monge, Alessandro Padovani, Alessandro Tessitore, Alessandro Stefani and 2 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Roberta BovenziDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Claudio LiguoriDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. dott.claudioliguori@yahoo.it.ORCID http://orcid.org/0000-0003-2845-1332
Margherita CanesiParkinson Institute, ASST Gaetano Pini CTO, Milan, Italy.
Marco D'AmelioDipartimento Di Biomedicina, Neuroscienze e Diagnostica Avanzata, Università Degli Studi di Palermo, Palermo, Italy.
Maria Francesca De PandisDepartment of Human Sciences and Promotion of Quality of Life, San Raffaele University, Rome, Italy.
Carmine MariniDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Alessandra MongeOspedale San Giovanni Battista, ACISMOM, Roma, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Alessandro TessitoreDepartment of Advanced Medical and Surgery Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Alessandro StefaniDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Mario ZappiaDepartment "G.F. Ingrassia", Section of Neurosciences, University of Catania, Catania, Italy.
SYNAPSES Study Investigators Italian Group
University of Catania · ITUniversity of Rome Tor Vergata · ITAzienda Ospedaliero Universitaria San Giovanni Battista · ITUniversity of L'Aquila · ITUniversity of Brescia · ITMoriggia Pelascini Hospital · ITUniversità degli studi di Cassino e del Lazio Meridionale · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSafinamide is a recent antiparkinsonian drug that modulates both dopaminergic and glutamatergic systems with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). Here, we aimed to describe the efficacy and safety of safinamide in the Italian PD patients in real-life conditions.

methodsWe performed a sub-analysis of the Italian cohort of the SYNAPSES study, a multi-country, multi-center, retrospective-prospective cohort observational study, designed to investigate the use of safinamide in routine clinical practice. Patients received for the first time a treatment with safinamide and were followed up for 12 months. The analysis was conducted on the overall population and in subgroups of interest: i) patients > 75 years, ii) patients with relevant comorbidities and iii) patients affected by psychiatric symptoms.

resultsItaly enrolled 616/1610 patients in 52 centers, accounting for 38% of the entire SYNAPSES cohort. Of the patients enrolled, 86.0% were evaluable at 12 months, with 23.3% being > 75 years, 42.4% with psychiatric conditions and 67.7% with relevant comorbidities. Safinamide was effective on motor symptoms and fluctuations as measured through the Unified PD rating scale III and IV scores, and on the total score, without safety issues in none of the subgroups considered.

conclusionThe SYNAPSES data related to Italian patients confirms the good safety profile of safinamide even in special groups of patients. Motor fluctuations and motor impairment improved at the follow-up suggesting the significant role of safinamide in managing motor symptoms in PD patients.

Indexed as

BenzylaminesParkinson DiseaseAlanineAntiparkinson AgentsHumansLevodopaProspective StudiesRetrospective StudiesAlanineAntiparkinson AgentsBenzylaminesLevodopasafinamideMAO-B inhibitorParkinson’s diseaseReal-life evaluationSafetySafinamide

Identifiers

PMID37684511
PMCPMC10791801
OpenAlexW4386531948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.